Ian F. Parney

Jul 24, 2023 | nature.com | Ian F. Parney |Solmaz Sahebjam |Nader Sanai |Michael Platten |Michael Lim |Timothy F. Cloughesy | +11 more

A breakthrough in drug discovery for glioblastoma requires serial collection of tissue from the central nervous system via window of opportunity trials Therapeutic drug development in glioblastoma has remained static despite numerous clinical trials, advances in tumor biology, and substantial public interest. Since 2005, more than 1,250 interventional glioblastoma trials have been registered on ClinicalTrials.gov.